Medicus Pharma Secures Up to $22M Financing to Advance Clinical Programs

May 28, 2026

Medicus Pharma (NASDAQ: MDCX) announced a definitive financing agreement with an institutional investor providing for up to $22 million in structured funding, aimed at supporting the advancement of the company’s clinical development pipeline and therapeutic programs. The financing is expected to increase Medicus’ pro forma cash position to approximately $30 million and extend its projected operating runway beyond 24 months.

Under the agreement, Medicus will receive $12 million in immediate operating capital, while an additional $10 million will be held in a collateralized deposit account and released upon achievement of specified development milestones. The company says the funding strengthens its position as it advances potentially disruptive therapies through clinical development.

#MedicusPharma
#MDCX
#Biotech
#HealthcareInnovation
#ClinicalTrials
#DrugDevelopment
#Biotechnology
#Pharmaceuticals
#StockMarket
#Nasdaq
#MedicalResearch
#Healthcare
#Finance
#JaneKing
#NewsOut